FOXM1表达水平与晚期非小细胞肺癌临床病理特征及靶向药物疗效的关系

目的探讨非小细胞肺癌(NSCLC)叉头框转录因子M1(FOXM1)的表达水平及其与临床病理特征、靶向药物疗效之间的关系。方法收集新疆医科大学附属肿瘤医院2011-2014年病理确诊的NSCLC 80例,采用免疫组化方法检测组织中FOMX1的表达水平,并结合临床病理特征、靶向药物疗效进行分析。结果 FOMX1表达的阳性率为41.25%。不同年龄、性别、分期及吸烟史的NSCLC患者FOXM1蛋白的表达差异无统计学意义(P0.05)。不同分化程度、淋巴结转移状态的NSCLC患者FOXM1蛋白的表达差异有统计学意义(P0.05)。FOXM1蛋白表达阳性的患者使用靶向药物的无进展生存时间较FOXM1蛋白表达阴性患者短(P0.05)。结论 FOXM1的表达与病理分化程度及淋巴结转移有关,FOXM1表达阳性的患者使用靶向药物的无进展生存时间较表达阴性的患者短。

The relationship of FOXM1 expression and the clinical pathological factors andclinical response to target-therapy in advanced non-small cell lung cancer

Objective To explore the expression of FOXM1 in non-small cell lung cancer(NSCLC) and the relationship between FOXM1 expression and the clinical pathological factors,clinical response to target-therapy in NSCLC remained unknown.Methods A total of 80 NSCLC patients were recruited into this study,FOXM1 expression was assessed by immunohistochemistry and analyzed with the clinical pathological factors and clinical response to target-therapy.Results The positive rate of FOXM1 expression was 41.25%.The positive expression of FOXM1 had no significant difference in patients with different age,gender,cancer staging,smoking history(P>0.05),but had significant difference in patients with different degree of differentiation,lymph node metastasis(P<0.05).Survival time in patients with positive FOXM1 expression was significant shorter than that with negative FOXM1 expression(P<0.05).Conclusion The expression of FOXM1 closely correlated with patients histological differentiation,lymph node metastasis,progress-free survival time in patients with positive FOXM1 expression was significantly shorter than those with negative FOXM1 expression.